ASK PHARM(SZ:002755) Xin Lang Cai Jing·2025-10-17 00:38Core Insights - AskGene Pharma, a subsidiary of Aosaikang, has entered into a licensing agreement with Visara for its innovative drug project ASK712, which is currently in Phase IIa clinical trials for treating macular diseases [1] Licensing Agreement Details - The licensing agreement grants Visara exclusive rights to develop, manufacture, and commercialize ASK712 in several regions, including Greater China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, South Korea, and India [1] - Visara will pay an upfront fee of $7 million to AskGene Pharma, with potential milestone payments related to research, registration, and commercialization that could total up to $89 million [1] - AskGene Pharma will also receive a percentage of royalties based on the annual net sales of the product within the licensed regions [1]